INTRODUCTION
============

Caveolae, the plasma membrane invaginations on the luminal side of endothelial cell monolayer and the caveolae associated protein caveolin-1 (Cav-1), have a key homeostatic role in regulating caveolar functions such as the production of nitric oxide and caveolae-mediated trafficking ([@B42], [@B40]; [@B12]). Cav-1 is inserted into the caveolar plasma membrane where it serves as a primary structural and signaling protein ([@B36]; [@B39]; [@B38]; [@B8]; [@B7]). Mice with genetic deletion of Cav-1 (*Cav-1^−/−^*) failed to form caveolae ([@B10]; [@B50]) indicating the requirement of Cav-1 in caveolae biogenesis. Studies also showed that *Src* kinase-mediated phosphorylation of Cav-1 on Y-14 was required for the fission of caveolae from the plasma membrane and caveolae-mediated endocytosis and trafficking ([@B31]; [@B51]; [@B66]). The Cav-1 scaffold domain (CSD) binds various signaling proteins via the sequence in CSD-interacting proteins, the CSD binding motif (CSDBM). These proteins include *Src* tyrosine kinases, eNOS (endothelial nitric oxide synthase), and trimeric G protein subunits, Ras, and PPARγ ([@B28]; [@B13]; [@B20]; [@B35]; [@B52]; [@B11]; [@B5]; [@B4]; [@B6]; [@B25]). However, other studies based on assessing the structure of CSD/CSDBM interaction suggested that caveolin--protein interactions are rare ([@B9]).

Erythropoietin-producing hepatocellular carcinoma (Eph) receptor tyrosine kinases and their ligands, Ephrins, are expressed in multiple cell types including ECs ([@B3]; [@B22]). Eph receptors have an important role in regulating neuronal and vascular development, axon guidance, and cell-specific identities ([@B18]; [@B63]; [@B26]; [@B47]). Ephrins also regulate postnatal angiogenesis and vascular integrity ([@B46]; [@B26]; [@B47]; [@B34]; [@B57]) by mechanisms that are not clear. Most Eph receptors also exhibit the conserved CSDBM in their kinase domain indicative of a binding relationship with Cav-1 ([Figure 1A](#F1){ref-type="fig"}; [@B59]; [@B3]; [@B22]). In a study using CHO cells, EphB1 was shown to bind CSD via its CSDBM (^808^WSYGIVMW^815^; [@B59]). Furthermore, knockdown of EphB4 expressed in human umbilical vein ECs reduced Cav-1 phosphorylation on Y14 secondary to EphB4 activation by the ligand Ephrin B2 ([@B29]). These findings suggest a potential signaling link between Eph receptors and Cav-1; however, the details of this relationship and their functional significance remain incompletely understood. In the present study, we demonstrated that EphB1/Cav-1 interaction formed a signaling module that was required for the biogenesis of caveolae and function of caveolae in ECs. EphB1-dependent *Src* activation resulting in Cav-1 phosphorylation on Y14 induced caveolae-mediated endocytosis and trafficking.

![Colocalization of EphB1 and caveolin-1 (Cav-1) determined by 3D-structured illumination microscopy. (A) Schematic representation of structural domain features of EphB1 and Cav-1. CSD, Cav-1 scaffold domain; CSDBM, CSD binding motif in EphB1; LBD, ligand-binding domain; Cys, cysteine-rich domain; FNIII, fibronectin-type III repeats; TM, transmembrane domain; KD (dashed green line), EphB1 kinase domain (614--882). (B) Western analysis of human lung microvessel endothelial cells (HLMVECs) showing the expression of EphB1 and Cav-1. (C) HLMVECs stained with antibody specific to Cav-1 were used for 3D-structured illumination microscopy (3D-SIM) imaging. Representative sectional view of single cell plasma membrane image from 3D-SIM showing Cav-1+ve vesicular structures (caveola, 100 nm, left; caveolar clusters, 400 nm, right). (D) HLMVECs stained with antibodies specific to Cav-1 and EphB1 were used for 3D-SIM to assess colocalization of EphB1 with Cav-1. Representative sectional view of single cell plasma membrane image from 3D-SIM showing colocalization of EphB1 with Cav-1. In Merge, a magnified view of the region is shown. Scale bars correspond to 1 µm. (E) Colocalization efficiency of EphB1 and Cav-1 as assessed by Manders overlap coefficient is shown. *N* = 4 cells.](mbc-31-1167-g001){#F1}

RESULTS
=======

EphB1 colocalizes with Cav-1 in ECs
-----------------------------------

We studied the interaction of EphB1 with Cav-1 expressed in human lung microvascular ECs (HLMVECs; [Figure 1B](#F1){ref-type="fig"}). We initially used 3D-structured illumination microscopy (3D-SIM) superresolution microscopy in which the spatial resolution of an ∼100-nm structure could be resolved ([@B64]). We observed heterogeneous vesicular structures ranging from caveola of diameter 100 nm ([Figure 1C](#F1){ref-type="fig"}) to multilobed caveolar rosettes of 400 nm ([Figure 1C](#F1){ref-type="fig"}). EphB1 was predominantly colocalized with Cav-1 positive multilobed caveolar rosettes ([Figure 1D](#F1){ref-type="fig"}). Colocalization as quantified by measuring the Manders overlap coefficient ([@B30]) showed strong EphB1 with Cav-1 association ([Figure 1E](#F1){ref-type="fig"}).

Autophosphorylation of EphB1 uncouples EphB1 from Cav-1 to induce Y14 Cav-1 phosphorylation
-------------------------------------------------------------------------------------------

Because EphB1 and Cav-1 colocalized in caveolar microdomains, we next investigated the possibility that EphB1/Cav-1 interaction regulates the canonical Y-14 phosphorylation site of Cav-1 via *Src* activation, a critical mechanism of Cav-1 signaling ([@B31]; [@B51]; [@B66]). Here we added the EphB1 agonist Ephrin B1-Fc, the soluble Ephrin B1 extracellular domain fused to Fc fragment, ([@B3]; [@B22]), to wild-type (WT) murine lung ECs (from C57BL/6 mice). We observed marked tyrosine phosphorylation of EphB1 post---Ephrin B1-Fc stimulation ([Figure 2A](#F2){ref-type="fig"}). Interestingly, the binding of phosphorylated EphB1 binding to *Src* and phosphorylation of *Src* at Y416 (an indication of *Src* activation) occurred in the same time frame as EphB1 phosphorylation ([Figure 2A](#F2){ref-type="fig"}), a finding consistent with binding of SH2 domain of *Src* to phosphotyrosine on EphB1 responsible for triggering *Src* activation ([@B60]). Ephrin B1-Fc stimulation also induced intense phosphorylation of Cav-1 on Y14 site ([Figure 2B](#F2){ref-type="fig"}). Next, using 3D-SIM, we observed marked colocalization of EphB1 with Cav-1 in multilobed caveolar structures, which was markedly reduced within 5--10 min of adding Ephrin B1-Fc ligand ([Figure 2C](#F2){ref-type="fig"} and Supplemental Figure 1, A and B). These results are consistent with immunoprecipitation (IP) experiments showing that Ephrin B1--induced phosphorylation of EphB1 causes the dissociation of EphB1 from Cav-1, whereas dephosphorylated EphB1 promotes reassociation with Cav-1 ([Figure 2A](#F2){ref-type="fig"}). Because it is possible that other EphB receptors expressed in ECs may also be activated by Ephrin B1, we addressed whether the observed effects of the Ephrin B1 ligand were specific to the EphB1 receptor. Thus, we used the EphB1 selective antagonistic peptide (EphB1-A-pep; [Figure 2D](#F2){ref-type="fig"}; [@B23]; [@B45]), which prevents binding of Ephrin B1 to EphB1 ligand-binding domain, and inhibits EphB1 signaling ([@B23]; [@B45]). HLMVECs treated with EphB1-A-pep prevented Ephrin B1--induced EphB1 autophosphorylation ([Figure 2E](#F2){ref-type="fig"}) as well as *Src* activation (p-Y416; [Figure 2F](#F2){ref-type="fig"}) and phosphorylation of Cav-1 on Y14 as compared with control peptide ([Figure 2G](#F2){ref-type="fig"}), indicating the specificity of Ephrin B1 in activating its cognate receptor EphB1 in ECs.

![(A--C) Ephrin B1--induced autophosphorylation of EphB1 causes EphB1 binding to *Src*, phosphorylation of *Src* on Y-416, and Cav-1 on Y-14 to uncouple EphB1 from Cav-1. (A, B) ECs from WT mice were serum starved for 2 h and then exposed to Ephrin B1-Fc (1 µg/ml) for different times up to 60 min for immunoprecipitation followed by immunoblot (IB). In A, cell lysates were immunoprecipitated (IP-ed) with anti-EphB1 pAb and the IP-ed proteins were used for IB with specific antibodies indicated. In B, total cell lysates were used for IB. Results shown are representative of three experiments. \*\*, *p* \< 0.001, compared with basal. (C) WT ECs serum starved for 2 h and then exposed to Ephrin B1-Fc (1µg/ml) for different times up to 60 min, and immunostained with antibodies specific to EphB1 and Cav-1, were used for 3D-SIM imaging. Sectional images are of single cell plasma membrane from 3D-SIM showing changes in colocalization of EphB1 with Cav-1 at baseline and following stimulation with the ligand Ephrin B1-Fc. In Merge, a magnified view of the region is indicated. Scale bars correspond to 1 µm. The right panel shows the EphB1 and Cav-1 colocalization efficiency assessed by Manders overlap coefficient. *N* = 5 cells/group; \*, *p* \< 0.05, compared with basal. (D--G) EphB1-specific antagonistic peptide prevents Ephrin B1--induced autophosphorylation of EphB1, *Src* activation, and phosphorylation of Cav-1 on Y-14. (D) Sequences of EphB1 antagonistic peptide (EphB1-A-Pep) and control peptide (Control Pep) are shown. (E--G) HLMVECs incubated in serum-free condition for 2 h at 37°C were treated with EphB1-Ap-pep or control peptide (Control Pep) for 30 min. Cells were then exposed to EphrinB1 (EphrinB1-Fc; 1 μg/ml) for 10 min at 37°C. In E, cell lysates immunoprecipitated with anti-EphB1 pAb and blotted with anti-phosphotyrosine mAb to determine phosphorylation of EphB1. In F, total cell lysates were used to determine phosphorylation of *Src* at Y416 to assess *Src* activation. In G, total cell lysates were used to determine phosphorylation of Cav-1 on Y-14. (E--G) Blots shown are representative of three separate experiments. \*\*, *p* \< 0.001; control vs. EphB1-A-pep.](mbc-31-1167-g002){#F2}

Ligand Ephrin B1 prevents EphB1/Cav-1 interaction and induces *Src* activation and *Src*-dependent Y14 Cav-1 phosphorylation
----------------------------------------------------------------------------------------------------------------------------

To address the role of EphB1/Cav-1 complex in signaling *Src*-dependent Cav-1 phosphorylation, we first coexpressed WT-EphB1-YFP with either WT-Cav-1-CFP or the mutant EphB1^∆808-815^-YFP with WT-Cav-1-CFP in COS-1 cells, and determined the associations of each pair by 3D-SIM superresolution microscopy. We observed the colocalization of WT-EphB1-YFP with WT-Cav-1-CFP in caveolar rosette structures ([Figure 3B](#F3){ref-type="fig"} and Supplemental Figure 2, A and B) and markedly reduced colocalization of WT-EphB1-YFP with WT-Cav-1-CFP upon Ephrin B1-Fc addition ([Figure 3B](#F3){ref-type="fig"} and Supplemental Figure 2, A and B). Interestingly, the expression of mutant EphB1^∆808-815^ in which CSDBM was deleted prevented the colocalization EphB1 with WT-Cav-1-CFP ([Figure 3C](#F3){ref-type="fig"} and Supplemental Figure 2, A and B), indicating that CSDBM per se of EphB1 was required for EphB1 interaction with Cav-1.

![(A-D) EphB1 colocalization with caveolin-1 (Cav-1) scaffold binding domain (CSD) assessed by 3D-structured illumination microscopy (3D-SIM) and FRET. (A) Western analysis of COS-1 cells transfected with WT-EphB1-YFP (WT-EphB1 C-terminus fused with YFP), WT-Cav-1-CFP (WT-Cav-1 C-terminus fused with CFP), and EphB1∆808-815-YFP. (B) Sectional image of COS-1 cell expressing WT-EphB1 plus WT-Cav-1 using 3D-SIM showing CSDBM of EphB1 interacts with WT-Cav-1. *Top panel*, representative unstimulated cell sectional view of 3D image. *Bottom panel*, representative COS-1 cell sectional view of a 3D image showing the effect of Ephrin B1-Fc (1 µg/ml) stimulation, which caused EphB1 dissociation from Cav-1. *Right panel*, EphB1 and Cav-1 colocalization efficiency assessed by Manders overlap coefficient (MOC). *N* = 4 cells/group; \*, *p* \< 0.05, compared with basal. (C) Sectional images of COS-1 cell expressing EphB1^∆808-815^ plus WT-Cav-1 using 3D-SIM showing an absence of interaction between CSDBM-deleted EphB1 (EphB1^∆808-815^) and WT-Cav-1. *Top panel*, control. *Bottom panel*, stimulated with Ephrin B1-Fc (1 µg/ml). *Right panel*, colocalization efficiency between EphB1^∆808-815^ and Cav-1 assessed by MOC. (D) Live-cell FRET measurements in COS-1 cells showing dissociation of EphB1 from Cav-1 after challenging with Ephrin B1. CFP/YFP ratio before and after challenging cells with the ligand Ephrin B1 (Ephrin B1-Fc; 1 µg/ ml) are shown. Results shown are mean ± SE of three separate experiments. \*\*, *p* \< 0.001, compared with WT-EphB1 + WT-Cav-1 control (green) or EphB1^∆808-815^ + WT-Cav-1 (red) exposed to Ephrin B1. (E, F) Binding of CSDBM of EphB1 to CSD and EphB1 phosphorylation on Y^600^ are required for *Src* activation and Cav-1 phosphorylation on Y14. (E) WT-EphB1-YFP + WT-Cav-1-CFP, EphB1^∆808-815^-YFP+ WT-Cav-1-CFP, or EphB1^Y600F^-YFP + WT-Cav-1-CFP expressing Cos-1 cells IP-ed with anti-EphB1 pAb and immunoblot with anti-Cav-1 pAb or anti-EphB1 mAb. (F) WT-EphB1-YFP + WT-Cav-1-CFP, EphB1^∆808-815^-YFP+ WT-Cav-1-CFP, or EphB1^Y600F^-YFP + WT-Cav-1-CFP expressing Cos-1 cells were stimulated with or without EphrinB1-Fc (1 μg/ml) for 10 min. Cell lysates were IP-ed with anti-GFP mAb (anti-GFP mAb immunoprecipitates both YFP- tagged EphB1 and CFP-tagged Cav-1) and were blotted with indicated antibodies. Results shown are representative of three experiments. \*, *p* \< 0.01.](mbc-31-1167-g003){#F3}

We next carried out fluorescence resonance energy transfer (FRET) studies to assess further the interaction between EphB1 and Cav-1. Here we coexpressed WT-EphB1-YFP with either WT-Cav-1-CFP or the mutant EphB1^∆808-815^-YFP with WT-Cav-1-CFP in COS-1 cells. We observed fourfold greater FRET intensity in the cells coexpressing WT-EphB1-YFP and WT- Cav-1-CFP than the cells expressing EphB1^∆808-815^-YPF and WT-Cav-1-CFP ([Figure 3D](#F3){ref-type="fig"}). Stimulation of cells coexpressing WT-EphB1-YFP and WT-Cav-1-CFP with Ephrin B1-Fc showed markedly reduced FRET intensity ([Figure 3D](#F3){ref-type="fig"}), whereas cells coexpressing EphB1^∆808-815^-YPF and WT-Cav-1-CFP showed no response ([Figure 3D](#F3){ref-type="fig"}), further supporting the essential role of Ephrin B1 ligand binding to EphB1 in causing the dissociation of EphB1 from Cav-1.

As EphB1 autophosphorylation on Y600 was to mediate *Src* binding and activation ([@B60]), we next determined whether EphB1 CSDBM binding to Cav-1 was required for the ligand Ephrin B1--mediated *Src* activation secondary to autophosphorylation of EphB1 at Y600. Here we coexpressed WT-EphB1-YFP with either WT-Cav-1-CFP, mutant EphB1^∆808-815^-YFP with WT-Cav-1-CFP, or mutant EphB1^Y600F^-YFP with WT-Cav-1-CFP in COS-1 cells ([Figure 3, E and F](#F3){ref-type="fig"}). By IP analysis using anti--EphB1-specific antibody, we observed interaction between WT-EphB1 and WT-Cav-1 ([Figure 3E](#F3){ref-type="fig"}), whereas CSDBM-deleted mutant EphB1 (EphB1^∆808-815^) failed to interact with WT-Cav-1 ([Figure 3E](#F3){ref-type="fig"}). Interestingly, mutant EphB1^Y600F^-YFP binding to WT-Cav-1-CFP was not altered ([Figure 3E](#F3){ref-type="fig"}), indicating that phosphorylation of EphB1 was not a requirement for EphB1/Cav-1 interaction. Next we used anti-GFP antibody for immunoprecipitation, and immunoprecipitated samples were used to assess phosphorylation of EphB1, *Src*, and Cav-1. We observed autophosphorylation of EphB1 and phosphorylation of both *Src* on Y-416 and Cav-1 on Y-14 in WT-EphB1 and WT-Cav-1 coexpressing cells, which were increased in both cases by Ephrin B1-Fc ligand ([Figure 3F](#F3){ref-type="fig"}). In EphB1^∆808-815^ and WT-Cav-1 coexpressing cells, however, we observed basal as well as Ephrin B1--induced phosphorylation of EphB1, *Src* and Cav-1 were blocked ([Figure 3F](#F3){ref-type="fig"}). Similar results were obtained in mutant EphB1^Y600F^ and WT-Cav-1 coexpressing cells ([Figure 3F](#F3){ref-type="fig"}). These results collectively support the notion that the binding of CSD with CSDBM in EphB1 and autophosphorylation of EphB1 on Y600 are required for EphB1-mediated *Src* activation, and Cav-1 phosphorylation on Y-14.

EphB1/Cav-1 interaction regulates caveolae biogenesis
-----------------------------------------------------

We next studied EphB1-deleted mice (*EphB1^−/−^*) and mice expressing EphB1-tc (EphB1-βgal fusion receptor lacking the tyrosine kinase and C-terminal domains). Western blot analysis of lung tissue and isolated lung ECs showed the absence of EphB1 expression in *EphB1^−/−^* mice (Supplemental Figure 3, A and B) and the expression of EphB1-βgal fusion receptor in EphB1-tc mice (Supplemental Figure 3, A and B). Immunostaining of lung sections from EphB1-tc mice with antibodies to β-gal and vWF (an EC marker) showed β-gal expression in blood vessels (Supplemental Figure 3C). Using *EphB1^−/−^* mice to study whether EphB1 affected Cav-1 expression in vivo, we found that Cav-1 protein expression was markedly reduced in *EphB1^−/−^* mice as compared with WT ([Figure 4A](#F4){ref-type="fig"}). Interestingly, decreased Cav-1 protein expression was not associated with reduced Cav-1 mRNA in *EphB1^−/−^* mice ([Figure 4B](#F4){ref-type="fig"}), indicating that EphB1 posttranscriptionally regulated Cav- 1 expression. As Cav-1 is known to be ubiquitinated and degraded via a proteasomal pathway ([@B17]; [@B2]), we assessed the possibility of ubiquitination of Cav-1 in ECs of *EphB1^−/−^* mice, and showed increased Cav-1 ubiquitination in ECs from *EphB1^−/−^* mice as compared with WT ECs ([Figure 4C](#F4){ref-type="fig"}). In intestinal epithelial cells, siRNA-mediated suppression of lipid raft-associated protein flotillin-1 promoted Cav-1 degradation via lysosomal pathway ([@B58]). Because Cav-1 expression was markedly reduced in EphB1-deficient mice, we address the possibility that EphB1 may regulate Cav-1 expression through suppressing flotillin-1 in ECs. We observed that flotillin-1 expression in lung tissue and ECs was not different between WT and *EphB1^−/−^* mice ([Figure 4D](#F4){ref-type="fig"}), suggesting that EphB1 direct binding to Cav-1 prevents Cav-1 degradation in ECs and that flotillin-1 was not involved. Next we assessed the expression of the caveolar coat proteins cavin-1 and -2 ([@B16]; [@B24]). It has been shown that cavin-2 is required for caveolar structure formation in murine lung ECs ([@B16]). We observed that cavin-1 expression was not different between the genotypes, but cavin-2 expression was increased in *EphB1^−/−^* mice ([Figure 4E](#F4){ref-type="fig"}), suggesting that cavin-2 accumulates in ECs in the absence of EphB1, perhaps because of the defective formation of caveolae in ECs of *EphB1^−/−^* mice ([Figure 5](#F5){ref-type="fig"}). We next carried out an ultrastructural analysis and observed markedly impaired caveolar morphogenesis in lung and heart microvascular endothelia of *EphB1^−/−^* mice ([Figure 5, A and B](#F5){ref-type="fig"}). The number of caveolae was significantly reduced in ECs of lungs ([Figure 5A](#F5){ref-type="fig"}, right panel; 4.2 ± 0.2/μm in WT mice vs. 1.3 ± 0.2/μm *EphB1^−/−^* mice) and hearts (5.4 ± 0.3/μm in *EphB1^+/+^* mice vs. 2.6 ± 0.3/μm *EphB1^−/−^* mice; [Figure 5B](#F5){ref-type="fig"}, right panel). However, there were no differences in caveolar shapes in these ECs ([Figure 5, A and B](#F5){ref-type="fig"}) and in interendothelial junctions (Supplemental Figure 4). 3D-SIM superresolution microscopy demonstrated that the number of caveolae (defined as Cav-1--positive structures) was also markedly reduced in ECs of *EphB1^−/−^* mice, and caveolar rosette-like structures in ECs formed by fusion of multiple caveolae were not seen in ECs from *EphB1^−/−^* mice as compared with WT ECs ([Figure 5C](#F5){ref-type="fig"}).

![EphB1 regulates the expression of Cav-1. (A) Lung and heart tissues from WT (*EphB1^+/+^*) and EphB1 knockout (*EphB1^−/−^*) mice were used for Western blotting to determine Cav-1 expression. *n* = 5 mice per group; unpaired *t* test. \*, *p* \< 0.05. (B) EphB1 deficiency did not alter Cav-1 mRNA expression. Quantitative real-time PCR was performed utilizing total RNA from lung tissue of WT and *EphB1^−/−^* mice to determine mRNA expression for Cav-1α and Cav-1β isoforms. (C) EphB1 deficiency induced Cav-1 degradation via ubiquitination. Freshly isolated lung ECs from WT and *EphB1^−/−^* mice were IP-ed with anti--Cav-1 mAb and blotted with anti--pan-ubiquitin (Ubi) pAb. *n* = 5 mice per genotype used for EC isolation; unpaired *t* test. \*, *p* \< 0.05. (D) EphB1 deficiency did not alter flotillin-1 expression. Lung tissue and lung ECs (ECs) from WT (*EphB1^+/+^*) and *EphB1^−/−^* mice were used to determine flotillin-1 expression by Western analysis. *n* = 4 mice per group; three separate EC preparations were used. Unpaired *t* test. NS, not significant. (E) Expression of caveolar coat proteins Cavin-2 but not Cavin-1 was increased in *EphB1^−/−^* mice. Lung tissue and lung ECs (ECs) from WT (*EphB1^+/+^*) and *EphB1^−/−^* mice were used to determine Cavin-1 and Cavin-2 by Western analysis. *n* = 5 mice per group; three separate EC preparations were used. Unpaired *t* test. \*, *p* \< 0.05.](mbc-31-1167-g004){#F4}

![EphB1 is required for caveolae morphogenesis in endothelial cells. (A) Electron micrograph showing reduced caveolae number in lung endothelia of *EphB1^−/−^* mice with morphometric data in right panel. Caveolae open at the cell surface were counted per micrometer of endothelial luminal plasma membrane. Multiple electron micrographs were used for counting caveolae; *EphB1^+/+^* (WT) lungs, *n* = 67; *EphB1^−/−^* lungs, *n* = 66. L, lumen; EC, endothelium; *p* \< 0.0001 vs. *EphB1^+/+^*. (B) Electron micrograph showing reduced caveolae number in heart endothelia of *EphB1^−/−^* mice with morphometric data in right panel. *EphB1^+/+^* (WT) hearts, *n* = 31; *EphB1^−/−^* hearts, *n* = 40. L, lumen; *p* \< 0.0001 vs. *EphB1^+/+^*. (C) 3D-SIM superresolution microscopy image showing reduced number of Cav-1+ve structures in *EphB1^−/−^*-ECs. ECs from WT and *EphB1^−/−^* mice were stained with anti--Cav-1 pAb and used to obtain images by 3D-SIM superresolution microscopy. Representative sectional view of single cell plasma membrane image from 3D-SIM superresolution microscopy showing Cav-1+ve vesicles in lung endothelial cells from *EphB1^+/+^* and *EphB1^−/−^* mice. *n* = 5 cells per genotype; \*, *p* \< 0.05.](mbc-31-1167-g005){#F5}

EphB1-dependent Y-14 phosphorylation of Cav-1 regulates caveolae endocytosis and endothelial permeability
---------------------------------------------------------------------------------------------------------

To address next whether EphB1 regulates caveolae-mediated endocytosis, we compared responses in ECs from *EphB1^−/−^* and *Cav-1^−/−^* mice. Ephrin B1 induced time-dependent increases in phosphorylation of *Src* on Y-416 and Y-14 Cav-1 in WT ECs, whereas these responses were prevented in ECs from *Cav-1^−/−^* mice ([Figure 6, A and B](#F6){ref-type="fig"}). In ECs from *EphB1^−/−^* mice, we observed that Ephrin B1--induced phosphorylation on *Src* Y-416 and Cav-1 Y-14 were also blocked ([Figure 6, C and D](#F6){ref-type="fig"}). We also assessed using ECs from *EphB1^−/−^* and *Cav-1^−/−^* mice whether EphB1/Cav-1 interaction was required for signaling caveolae-mediated endocytosis. Caveolae endocytosis was determined by quantifying the uptake of tracer albumin Alexa Fluor--594--labeled bovine serum albumin tracer (Alexa Fluor--594 BSA; [@B19]; [@B66]). ECs were incubated with serum-free medium for 2 h followed by the addition of Ephrin B1-Fc ligand (1 µg/ml) in the medium containing 100 µg/ml albumin tracer plus 2 mg/ml unlabeled albumin. Analysis of single cell 3D images showed albumin internalization in WT ECs as early as 5 min after tracer addition. We observed 16 ± 3 particles/cell with maximum uptake of 850 ± 14 particles/cell attained at 60 min ([Figure 7A](#F7){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Numerous Cav-1--positive caveolae were seen in ECs of WT mice ([Figure 7A](#F7){ref-type="fig"}), whereas ECs from *EphB1^−/−^* mice showed fourfold reduction in albumin tracer internalization (in WT ECs 850 ± 14 particles/cell at 60 min vs. in *EphB1^−/−^* ECs 216 ± 16 particles/cell; [Figure 7, A and B](#F7){ref-type="fig"}, and [Table 1](#T1){ref-type="table"}). The uptake of albumin was also inhibited in *Cav-1^−/−^* ECs ([Figure 7, C and D](#F7){ref-type="fig"}, and [Table 1](#T1){ref-type="table"}) similar to ECs from *EphB1^−/−^* mice. To next address in vivo relevance of EphB1/Cav-1 interaction in mediating transendothelial albumin permeability, we used tracer ^125^I-albumin ([@B55]). *EphB1^−/−^* mice showed marked reduction in endothelial ^125^I-albumin permeability as compared with WT ([Figure 7E](#F7){ref-type="fig"}), and furthermore, treatment with anti-EphB1 pAb receptor blocking antibody significantly reduced ^125^I-albumin permeability in vivo ([Figure 7F](#F7){ref-type="fig"}).

![EphB1/Cav-1 interaction is required for Y-416 phosphorylation on *Src* (A, C) and Cav-1 phosphorylation on Y-14 (B, D). ECs from *Cav-1^+/+^* (WT), *Cav-1^−/−^, EphB1^+/^*^+^ (WT), and *EphB1^−/−^* mice exposed to EphrinB1 (EphrinB1-Fc; 1 µg/ml) for the indicated times were used for immunoblotting to determine phosphorylation of *Src* on Y-416 (left panels) and Cav-1 on Y-14 (pY14-Cav-1; right panels). Blots shown are representative of three to four separate experiments. Values are shown as mean ± SE. \*, *p* \< 0.05; \*\*, *p* \< 0.001; compared with controls; WT-LECs (lung endothelial cells) vs. *Cav-1^−/−^* or *EphB1^−/−^*.](mbc-31-1167-g006){#F6}

![(A--D) EphB1 is required for caveolae-mediated endocytosis and albumin permeability. (A) WT ECs (EphB1^+/+^); (B) *EphB1^−/−^*-ECs; (C) Cav-1^+/+^-ECs; (D) *Cav-1^−/−^-*ECs. (A--D) Representative 3D images of single cell labeled with Cav-1 (green) and albumin tracer (red) tracking from apical and basal aspects of ECs are shown. Images in each 3D-SIM data set were processed using the Particle Analysis function in Image J software. Results show the time course of Ephrin B1-Fc (1 µg/ml) --induced albumin internalization and passage from apical to basal aspects of ECs (A--C, bottom panels, and D, left panel). (A) apical side; (B) basolateral side. \*, *p* \< 0.05; \*\*, *p* \< 0.001; compared with 0 min. Transendothelial permeability of tracer ^125^I-albumin measured in wild-type (*EphB1^+/+^*) and *EphB1^−/−^* mice. *n* = 5 per group (E). Anti-EphB1 pAb (5 μg/ml) prevents transendothelial permeability of tracer ^125^I-albumin in WT mice similarly compared with control antibody (F). *n* = 5 per group (*EphB1^+/+^*). (G) Model for EphB1/Cav-1 signaling in mediating caveolae endocytosis and albumin permeability in ECs.](mbc-31-1167-g007){#F7}

###### 

Albumin tracer particles/EC determined by 3D-SIM superresolution microscopy.

  Time (min)   *EphB1^+/+^*   *EphB1^−/−^*   *Cav-1^+/+^*   *Cav-1^−/−^*
  ------------ -------------- -------------- -------------- --------------
  0            0 ± 0          0 ± 0          0 ± 0          0 ± 0
  5            16 ± 3         2 ± 2\*\*      9 ± 2          0 ± 0\*\*
  10           175 ± 14       37 ± 13\*\*    170 ± 13       9 ± 7\*\*
  30           350 ± 8        55 ± 13\*\*    308 ± 9        35 ± 15\*\*
  60           850 ± 14       216 ± 16\*\*   699 ± 17       58 ± 15\*\*

Values are mean ± SE; *n* = 5/cells/genotype.

*\*\**, *p* \< 0.001; *EphB1^+/+^-*ECs vs. *EphB1^−/−^-*ECs; *\*\**, *p* \< 0.001; *Cav-1^+/+^-*ECs vs. *Cav-1^−/−^-*ECs.

DISCUSSION
==========

We describe a functionally important interaction in ECs between the receptor tyrosine kinase EphB1 with the canonical caveolar protein Cav-1 in regulating the activation of *Src* and *Src-*mediated phosphorylation of Cav-1 on Y14. *Src* signaling induced by the uncoupling of EphB1/Cav-1 interaction mediated caveolar endocytosis and trafficking. We showed that CSDBM of EphB1 binds via the scaffold domain of Cav-1 (CSD), and thus constitutively masks the EphB1 kinase domain and holds *Src* in abeyance. However, activation of EphB1 by its native ligand Ephrin B1 uncoupled EphB1 from Cav-1, exposing the EphB1 kinase domain to activate *Src* and thereby induce *Src*-dependent phosphorylation of Y-14 Cav-1, the phosphoactive site on Cav-1 responsible for caveolae-mediated endocytosis ([@B31]; [@B51]; [@B66]).

Multiple signaling proteins have been shown to bind CSD ([@B28]; [@B13]; [@B20]; [@B35]; [@B52]; [@B11]; [@B5]; [@B4]; [@B6]; [@B25]). However, on the basis of structural and bioinformatic analysis, it appears that physical interactions between CSD and CSDBM are less common than previously believed ([@B9]). CSDBM is buried in the membrane making it inaccessible to bind many CSD-containing proteins ([@B9]; [@B1]). Thus far, only *Src* kinases (*Src, Fyn*) and dynamin-2 were shown to definitively bind nonphosphorylated Cav-1, whereas TRAF2 was shown to bind to Y-14 phosphorylated Cav-1 ([@B21]). Our results based on biochemical, genetic, superresolution microscopy and FRET analysis showed clear evidence of interaction of EphB1 with CSD of nonphosphorylated Cav-1 via the EphB1 CSDBM.

Ephrin ligation of Eph receptors mediates conformational changes in Eph receptors important for the activation of *Src* tyrosine kinase ([@B3]; [@B22]). Phosphorylation of the conserved Y-600 in the cytoplasmic juxta-membrane region of EphB1 both recruited and activated *Src* ([@B60]). We observed by immunoprecipitation, 3D-SIM superresolution imaging, and FRET analysis that the ligand Ephrin B1 induced dissociation of the receptor EphB1 from Cav-1. This uncoupling unmasked EphB1 kinase domain (which contains the CSDBM) to autophosphorylate EphB1 at Y-600 and induce *Src* kinase activation and Y-14 Cav-1 phosphorylation. We observed that coexpression of mutant EphB1^Y600F^ with WT-Cav-1 failed to phosphorylate *Src* on Y416 as well as Cav-1 on Y-14. These findings show that *Src* activation is a key signaling switch responsible for EphB1/Cav-1 dissociation and phosphorylation of Y-14 Cav-1, the requisite signal for caveolae-mediated endocytosis ([@B31]; [@B51]; [@B66]). An important unknown, however, is how a conformation change induced by Ephrin B1 binding to EphB1 leads to *Src* phosphorylation and downstream signaling.

Deletion of Cav-1 prevented the formation of caveolae ([@B10]; [@B50]; [@B8]) indicating that Cav-1 expression is essential for caveolae biogenesis in ECs. CSD is required for caveolae biogenesis because caveolae also did not form upon deletion of CSD ([@B1]). In the present study, we observed that deletion of CSDBM on EphB1 disrupted the formation of caveolae. That both Cav-1 and EphB1 induced similar caveolae biogenesis defects suggests that EphB1/Cav-1 interaction through CSD/CSDBM is a critical determinant of the formation of caveolae. An important question is why other proteins interacting with CSD of Cav-1 such as eNOS did not influence the genesis of caveolae ([@B41]). We showed that the transmembrane EphB1 was basally associated with Cav-1 at the plasma membrane unlike eNOS ([@B52]; [@B5]). Thus, constitutive association of Cav-1 with EphB1 in the plasmalemma may stabilize Cav-1 and facilitate the formation of homo-oligomers or hetero-oligomers with Cav-2, and hence contribute to caveolae formation ([@B38]; [@B7]).

We demonstrated that *Src-*dependent Cav-1 phosphorylation on Y-14 was essential for signaling caveolae-mediated endocytosis in ECs ([@B31]; [@B51]; [@B66]). Using ECs from *EphB1^−/−^* mice, we observed that Ephrin B1 failed to induce *Src* activation and Cav-1 phosphorylation. Furthermore, caveolae-mediated endocytosis was also abrogated in ECs of *EphB1^−/−^* mice. These findings together show that EphB1 signaling is a critical upstream regulator of Cav-1--mediated caveolar endocytosis and trafficking.

There are multiple reports of internalization of plasma albumin in caveolae and caveolar trafficking across the endothelium by a specialized transport mechanism ([@B14]; [@B49]). However, the normally high plasma albumin concentration of 3--4 g% suggests that such a mechanism should be fully saturated, hence the role of caveolae in trafficking macromolecular cargo such as albumin across endothelium has remained unsettled and controversial ([@B9]; [@B8]; [@B21]). In the endothelium of the developing vasculature, Ephrin B2 was shown to regulate vascular endothelial growth factor receptor endocytosis ([@B48]; [@B62]). Furthermore, Ephrin B2 signaling-mediated distribution of platelet-derived growth factor receptor β (PDGFRβ) to the Cav-1--positive membrane microdomains suppressed PDGFRβ-mediated downstream signaling in vascular smooth muscle cells ([@B33]). The findings of these studies circumstantially raise the possibility that Ephrin signaling in endothelium could modulate endocytosis of caveolae by localizing the Eph receptor tyrosine kinases in the caveolar microdomains.

In the present study, we demonstrated that soluble Ephrin B1 binding to EphB1/Cav-1 complex induced *Src* phosphorylation on Y-14 Cav-1 and activated caveolae-mediated endocytosis and the caveolar transport machinery. Studies have shown that soluble Ephrins can function as ligands for distant cell localized Eph receptors ([@B65]; [@B27]). Therefore, it is possible that soluble Ephrins in the circulation may activate EphB1/Cav-1 signaling complex in endothelial cell surface. If this is the case, the question arises as to how soluble Ephrins are generated in the circulation. One possible mechanism could be through metalloprotease-mediated shedding of Ephrin B1 from platelets and Ephrin B2 from ECs ([@B44], [@B43]; [@B27]; [@B32]). Another mechanism could involve release of Ephrin B2 containing extracellular vesicles (exosomes or microparticles) by ECs ([@B15]; [@B37]). Thus, EphB1 ligation by Ephrins B1/2 generated in plasma ([@B46]; [@B3]; [@B15]) may itself activate caveolar trafficking via *Src*-mediated Y-14 phosphorylation of Cav-1. This concept needs testing but it is consistent with the observation that *EphB1^−/−^* mice showed markedly reduced transendothelial ^125^I-albumin permeability as compared with WT mice.

MATERIAL AND METHODS
====================

Antibodies and other reagents
-----------------------------

Anti--Cav-1 rabbit polyclonal (cat. \#610059), anti--phos-Y14-Cav-1 mouse monoclonal (cat. \#611338), and anti--flotillin-1 mouse monoclonal (cat. \#610821) antibodies were from BD Transduction (San Jose, CA). Anti-*Src* rabbit monoclonal (cat. \#21235), anti--phos-Y416 *Src* rabbit polyclonal (cat. \#21015), and pan anti-ubiquitin polyclonal (cat. \#3933S) antibodies were obtained from Cell Signaling (Danvers, MA). Anti--cavin-1 (PTRF) pAb (cat. \#18892-1) and anti--Cavin-2 (SDPR) pAb (cat. \#12339-1) were from ProteinTech group (Chicago, IL). Chicken polyclonal β-galactosidase antibody (cat. \#ab9361) was from Abcam. Rabbit polyclonal von Willebrand factor antibody (cat. \#AB7356) obtained from Millipore Corp. Rabbit polyclonal antibody against EphB1 sequence (AA 528-541, DDDYKSELREQLPL; anti-EphB1 pAb) was custom produced by Sigma-Aldrich (St. Louis, MO). Anti-EphB1 mouse monoclonal against EphB1 sequence (AA 528-541, DDDYKSELREQLPL) was custom made by GenScript. EphB1 panning (receptor antagonistic) peptide (EWLSPNLAPSVRGSGSK) and scrambled control peptide (RTVAHHGGLYHTNAEVK) were synthesized by GenScript. PCR primers were custom synthesized from Integrated DNA technologies. Mouse recombinant EphrinB1-Fc chimera (cat. \#E0653-200UG) and BSA (cat. \#05470-1G) with purity \>98% were from Sigma. Alexa Fluor--594 BSA (cat. \#A13101), Alexa Fluor--488 chicken anti-rabbit (cat. \#A21441), and Alexa Fluor--647 goat anti-mouse (cat. \#A21236) were from Life Technologies (Carlsbad, CA). Tracer ^125^I-human serum albumin was from AnazaoHealth (Tampa, FL).

Mice
----

EphB1-deficient (*EphB1^−/−^*) and EphB1-tc (EphB1-βgal fusion receptor lacking the tyrosine kinase and C-terminal domains) mice generated on a CD1 background ([@B18]; [@B63]). Caveolin-1--deficient (*Cav-1^−/−^*) mice on a C57BL/6J background ([@B50]) were from Jackson Labs. Age-matched *EphB1^+/+^*, *EphB1^−/−^*, *EphB1-tc*, *Cav-1^+/+^*, and *Cav-1^−/−^* littermates were used for all experiments. All mice were housed in the University of Illinois Animal Care Pathogen Free Facility in accordance with institutional guidelines and guidelines of the U.S. National Institutes of Health. Veterinary care of these animals and related animal experiments was approved by the University of Illinois Animal Resources Center.

Quantitative real-time PCR
--------------------------

Total RNA was isolated from lung tissue and reverse transcribed with oligo(dt) primers and SuperScript reverse transcriptase (Invitrogen). The cDNA obtained was mixed with SYBR Green PCR mix (AB Applied Biosystems). An ABI prism 7000 was used for quantitative PCR. GAPDH expression served as an internal control. The following primers were used: mouse Cav-1α forward, 5′-AATACGTAGACTCCGAGGGACA-3′, and reverse, 5′-GACCACGTCGTCGTTGAGAT-3′; mouse Cav-1β, forward, 5′-TGAACTTTTCTTCCCACCGCT-3′, and reverse, 5′-TCAAAGTCAATCTTGACCACGTC-3′; GAPDH forward, 5′-ACCCAGAAGACTGTGGATGG-3′, and reverse, 5′-CACATTGG­GGGTAGGAACAC-3′.

Expression constructs and transfection
--------------------------------------

C-terminal CFP-tagged Cav-1 was prepared as described previously ([@B66]). pcDNA3 vector expressing mouse EphB1 C-terminal YFP-tagged (WT-EphB1-YFP), C-terminal YFP-tagged EphB1^∆808-815^ (EphB1^∆808-815^-YFP), and C-terminal YFP-tagged EphB1^Y600F^ (EphB1^Y600F^-YFP) were custom prepared by GenScript. DNA sequencing was performed to verify all the expression constructs sequences. COS-1 cells plated on 60-mm dishes at 60% confluency were transfected with WT-Cav-1-CFP (1 µg) plus WT-EphB1-YPF (2.5 µg), WT-Cav-1-CFP (1 µg) plus EphB1^∆808-815^-YFP (2.5 µg), or WT-Cav-1 (1 µg) plus EphB1^Y600F^-YFP (2.5 µg using Superfect transfection reagent (cat. \#301305; Qiagen). Media was replaced 6 h after transfection with fresh DMEM media containing 10% fetal bovine serum. After 72 h, cells were harvested and lysed in radio­immunoprecipitation assay buffer containing protease and phosphatase inhibitor cocktails. For 3D-SIM imaging experiments, 24 h after transfection, cells were plated on high-tolerance coverslips (pcs-170-1818; MatTek), and at 72 h, cells were used for experiments.

Live-cell FRET imaging
----------------------

Live-cell FRET imaging was performed as described previously ([@B66]).

ECs
---

HLMVECs and endothelial growth media-2 (EGM-2) were purchased from Lonza (Walkersville, MD). Lung ECs from mice were isolated with mAb to the adhesion molecule CD31 (PECAM-1; [@B54]).

Immunoblotting
--------------

ECs were washed three times with phosphate-buffered saline (PBS) at 4°C and lysed in lysis buffer (50 mM Tris-HCl, pH, 7.5, 150 mM NaCl, 1 mM EGTA, 1% Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 10 μM orthovanadate, and protease-inhibitor mixture; [@B56]). Mouse tissues were homogenized in lysis buffer ([@B56]). EC lysates or tissue homogenates were resolved by SDS--PAGE on a 4--15% gradient separating gel under reducing conditions and transferred to a Duralose membrane. Membranes were blocked with 5% dry milk in TBST (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween-20) for 1 h at RT and then incubated with the indicated primary antibody diluted in blocking buffer overnight at 4°C. For phospho-specific blots, membranes were incubated overnight at 4°C with the primary antibody diluted in TBST containing 5% BSA. Next, membranes were washed three times and incubated with appropriate HRP-conjugated secondary antibody. Protein bands were detected by enhanced chemiluminescence.

Immunostaining
--------------

Cells grown on high-tolerance coverslips (pcs-170-1818; MatTek) were incubated with serum-free medium (5 mM HEPES/HBSS, pH 7.4) for 2 h and stimulated with Ephrin B1-Fc (1 µg/ml) for indicated time periods. Cells were washed, fixed with 3% paraformaldehyde (PFA) in Hank's balanced salt solution (HBSS), permeabilized with 0.1% Tween-20 in 5 mM HEPES/HBSS, pH 7.4, and blocked with 5% human serum diluted with 5 mM HEPES/HBSS, pH 7.4 (blocking buffer) for 2 h at room temperature. After blocking, cells were incubated with primary antibodies (1 µg/ ml) anti- EphB1 mouse mAb or anti-Cav-1 rabbit mAb in blocking buffer overnight at 4°C. Cells were washed and incubated with 1 µg/ml secondary antibody Alexa Fluor--647 goat anti-mouse and Alexa Fluor--488 chicken anti-rabbit for 1 h. After washing, coverslips were mounted on microscope slides with ProLong Gold antifade reagent (Invitrogen).

Immunoprecipitation
-------------------

Cell lysate (150 µg protein) was subjected to immunoprecipitation. Each sample was incubated overnight with 1 µg/ml of the indicated antibody at 4°C. The next day, protein A/G beads were added to the sample and incubated for 1 h at 4°C. Immunoprecipitates were then washed three times with wash buffer (Tris-buffered saline containing 0.05% Triton X-100, 1 mM Na~3~VO~4~, 1 mM NaF, 2 µg/ml leupeptin, 2 µg/ml pepstatin A, 2 µg/ml aprotinin, and 44 µg/ml phenylmethylsulfonyl fluoride). Immunoprecipitated proteins were used for immunoblotting.

3D-SIM
------

All 3D-SIM imaging was performed on a DeltaVision OMX SR system (GE) equipped with an Olympus 60×/1.42 NA objective and refractive index matched immersion oil (*n* = 1.516--1.518) at room temperature. Full-frame structure illuminated image sequences were taken at 125 nm *Z*-axis sections for multiple *Z* positions; the same exposure and excitation parameters were undertaken to avoid pixel saturation and maintain the validity of comparison across samples. 3D-SIM images were reconstructed using Softworx (Applied Precision) offline using a Wiener filter coefficient of 0.001. Reconstructed 3D-SIM data was further processed by Imaris software (Bitplane; Zurich, Switzerland). To ensure colocalization accuracy, all color channels in the 3D-SIM system have been aligned using standard samples. The image in each 3D data set was processed using the Particle Analysis function in ImageJ to quantify the number and intensity of specific protein particles in each *Z* section.

Transmission electron microscopy
--------------------------------

WT and *EphB1^−/−^* mice were anesthetized with ketamine/xylazine (100 mg kg/5 mg kg) by intraperitoneal injection. Harvested organs were perfused with HBSS containing EM fixative (2% glutaraldehyde, 3% PFA, 0.1 M sodium cacodylate, pH 7.2). Tissue blocks (1 × 2 mm) were prepared fixed in fresh fixative, rinsed in 0.1 M sodium cacodylate, postfixed in 1% OsO~4~ in 0.1 M sodium cacodylate, rinsed, stained en bloc with Kellenberger's uranyl acetate in water, dehydrated through graded ethanol, and embedded in LX-112 resin using propylene oxide. Ultrathin sections of 20--40 nm were cut and mounted on grids, stained with uranyl acetate and lead citrate, and examined under a Joel 1220 electron microscope ([@B53]).

Caveolae endocytosis assay
--------------------------

Caveolae-mediated endocytosis of tracer albumin was measured as described ([@B31]; [@B51]). Briefly, ECs grown on high-tolerance coverslips (pcs- 170-1818; MatTek) were washed, incubated for 2 h in serum-free medium, followed by Alexa Fluor 594--conjugated albumin (0.1 mg/ml Alexa Fluor 594--BSA mixed into 2 mg/ml nonfluorescent BSA) in 5 mM HEPES-buffered HBSS at 37°C for up to 60 min ([@B31]; [@B51]). After this period of incubation, cells were washed, fixed with 3% PFA in HBSS, permeabilized with 0.1% Tween-20 in 5 mM HEPES/HBSS, pH 7.4, and blocked with 5% human serum diluted with 5 mM HEPES/HBSS, pH 7.4 for 2 h at RT. After blocking, cells were incubated with anti--Cav-1 rabbit mAb (1 µg/ml) in blocking buffer overnight at 4°C. Cells were washed and incubated with 1 µg/ml secondary antibody Alexa Fluor 488 chicken anti-rabbit for 1 h. After washing, coverslips were mounted on microscope slides with ProLong Gold antifade reagent (Invitrogen).

Endothelial permeability assay
------------------------------

We determined transendothelial permeability in lung vessels in WT or *EphB1^−/−^* mice were anesthetized using 2.5% sevoflurane in room air, and 2 µCi of ^125^I-labeled albumin tracer injected intravenously according to an approved animal protocol. At 30 min after tracer injection, a 100-µl blood sample was withdrawn from a vein to determine blood tracer counts. Organs were then cleared of circulating tracer by whole-body perfusion via the right heart using RPMI supplemented with 3% unlabeled albumin and lungs were excised and counted for γ-radioactivity. Transendothelial albumin permeability was calculated in ml/min/g dry tissue from blood and tissues counts, and values were normalized to tissue dry weight as described ([@B55]). To study the effects of the anti-EphB1 pAb on transendothelial albumin permeability, we used the method as described by us ([@B61]; [@B54]). Murine lungs were perfused via the pulmonary artery with RPMI solution containing 3% unlabeled albumin (2 ml/min, 37°C). All preparations underwent a 20-min equilibration perfusion, and then received control Ab or anti-EphB1 pAb via a side-arm of the pulmonary artery cannula to achieve a final perfusate concentration of 5 µg/ml each. The ^125^I-albumin tracer was infused via a separate side-arm for a 30-min period. A perfusate sample was collected to determine blood tracer counts and then washed out for 6 min, a period sufficient to reduce effluent counts to background levels. Lungs were counted for gamma radioactivity, and transendothelial albumin permeability was quantified in units of ml/min/g dry lung.

Statistical analysis
--------------------

Results were analyzed by unpaired two-tailed Student's *t* test. Differences in mean values were considered significant at *p* value \<0.05.
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